How does the mouse CD11a antibody help in elucidating the inhibition of macrophage function by the SIRPα-Cis-CD18 axis?

I. How is the phagocytic function of macrophages regulated in the tumor microenvironment?

In the tumor microenvironment, macrophages are one of the most abundant immune cell populations, and their functional state (pro-tumor M2 or anti-tumor M1) profoundly influences tumor progression. The phagocytic activity of macrophages is regulated by a delicate balance between "activation signals" and "inhibition signals." The classic "don't eat me" signal axis consists of signal regulatory protein α (SIRPα) on the macrophage surface and its widely expressed ligand CD47. When the extracellular domain of SIRPα binds to CD47 on target cells (trans-interaction), its intracellular immunoreceptor tyrosine-based inhibition motifs (ITIMs) are phosphorylated, recruiting phosphatases such as SHP-1/SHP-2 to transmit inhibitory signals, thereby preventing macrophages from phagocytosing CD47-positive cells. However, clinical therapies targeting this axis have limited efficacy and are associated with hematologic toxicity, suggesting the existence of other unknown regulatory mechanisms.

II. By what novel cis-acting mechanism does SIRPα inhibit macrophage function?

Recent breakthrough research has revealed that SIRPα's inhibition of macrophage function not only relies on the classic trans-interaction with CD47 but also involves a newly discovered "cis" inhibition mechanism. Studies show that on the macrophage's own cell membrane, SIRPα can directly bind physically to the integrin β2 subunit (CD18) on the same cell surface. CD18 combines with different α subunits (e.g., CD11a forming LFA-1, CD11b forming Mac-1) to form the functionally critical β2 integrin family. Among these, Mac-1 (CD11b/CD18) is a key effector molecule for macrophage phagocytosis, migration, and adhesion. The cis-binding of SIRPα to CD18 spatially hinders the transition of Mac-1 integrin from a low-affinity state to a high-affinity activated conformation, thereby inhibiting its effective binding to ligands such as intercellular adhesion molecule-1 (ICAM-1) and ultimately weakening the macrophage's phagocytic ability and anti-tumor immune response. Genetic mutations (e.g., the CD11b activating mutation I332G) or the use of Mn²⁺ to forcibly activate integrins can disrupt the SIRPα-CD18 cis-binding and restore macrophage phagocytic function.

III. What therapeutic potential do antibodies targeting different modes of SIRPα action have?

Based on the understanding of SIRPα's dual inhibition mechanisms, researchers have designed antibodies with different modes of action to evaluate their therapeutic potential: 1. Monospecific antibodies: Antibodies targeting either the SIRPα-CD47 binding site (trans-action) or the SIRPα-CD18 binding site (cis-action) can partially enhance macrophage phagocytosis of tumor cells in vitro. 2. Bispecific antibodies: Bispecific antibodies capable of simultaneously blocking SIRPα's trans-interaction with CD47 and its cis-interaction with CD18 exhibit the strongest synergistic effect. In preclinical models, this dual-function antibody increased macrophage phagocytic efficiency by more than twofold and, when combined with other therapies in immunodeficient mouse tumor models, showed significant tumor growth inhibition and extended survival. This validates that simultaneously lifting SIRPα's dual inhibition is an effective strategy for enhancing macrophage anti-tumor function.

IV. What is the application value of mouse CD11a antibodies in this mechanistic study?

In this research system, anti-mouse CD11a antibodies serve as tools for specifically recognizing the integrin αL subunit and hold significant research value. CD11a combines with CD18 to form lymphocyte function-associated antigen-1 (LFA-1). Although the focus is on how the SIRPα-CD18 interaction inhibits Mac-1 (CD11b/CD18), understanding whether this cis-inhibition mechanism is universal is crucial. Using anti-mouse CD11a antibodies, researchers can:

1. Assess mechanism specificity: Investigate whether the SIRPα-CD18 cis-binding similarly affects the activation and function of LFA-1 (CD11a/CD18). This helps determine whether the inhibition mechanism is specific to Mac-1 or universally applicable to all β2 integrins.

2. Analyze immune cell subsets: Through flow cytometry, combined with anti-CD11a, anti-CD11b, and anti-CD18 antibodies, researchers can finely analyze the expression and activation states of integrins on different myeloid cell subsets (e.g., macrophages, neutrophils) and lymphocytes in the tumor microenvironment.

3. Functional validation: In vitro functional experiments, anti-CD11a antibodies can block LFA-1-mediated cell adhesion, serving as controls or collaborative experiments to distinguish the specific contributions of different integrins to effector functions such as macrophage phagocytosis or T-cell killing.

V. What implications does the discovery of the SIRPα-Cis-CD18 axis hold for future immunotherapy?

The revelation of this new mechanism has important theoretical and clinical significance: 1. Unveils the multiple inhibition modes of immune checkpoints: It demonstrates that a single inhibitory receptor (e.g., SIRPα) can synergistically "brake" immune cell function through both trans (ligand-dependent) and cis (receptor-receptor) mechanisms. This suggests that other inhibitory receptors (e.g., PD-1, LILRB1) may also have undiscovered cis-regulatory partners. 2. Provides new strategies to overcome limitations of existing therapies: The design of bispecific antibodies targeting SIRPα (simultaneously blocking trans and cis interactions) offers a new approach to addressing the insufficient efficacy of targeting the CD47-SIRPα axis alone. 3. Expands understanding of integrin functional regulation: It directly links integrin activity regulation to immune checkpoint signaling, adding a new dimension to the understanding of immune suppression networks in the tumor microenvironment.

VI. Which manufacturers provide mouse CD11a antibodies?

Hangzhou Start Biotech Co., Ltd. has independently developed the "FITC Mouse Anti-Human CD11a Antibody (S-R402)" (Catalog No.: S0B1678), a ready-to-use flow detection antibody with high fluorescence brightness, excellent specificity, and stability. This product uses high-purity mouse anti-human CD11a monoclonal antibodies, optimized for fluorescein isothiocyanate (FITC) labeling, to efficiently and specifically bind to human CD11a (the αL subunit of LFA-1). It enables sensitive detection of leukocyte adhesion-related phenotypes in flow cytometry (FACS) analysis, serving as an important tool for studying immune cell migration, activation, and inflammatory responses.

Technical Support: We provide detailed product instructions, including recommended sample processing methods, staining conditions, and suggestions for incorporation into multicolor panels. Our technical team offers professional consultation on flow cytometry experimental design and optimization.

Hangzhou Start Biotech Co., Ltd. is committed to providing high-performance, high-quality antibody reagents for immunological research and clinical flow cytometry. For more information about the "FITC Mouse Anti-Human CD11a Antibody" (Catalog No. S0B1678), technical specifications, or sample requests, please feel free to contact us.

Product Information

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs

At ANTBIO, we are committed to advancing life science research through high-quality, reliable reagents and comprehensive solutions. Our specialized sub-brands (Absin, Starter, UA) cover a full spectrum of research needs, from general reagents and kits to antibodies and recombinant proteins. With a focus on innovation, quality, and customer-centricity, we strive to be your trusted partner in unlocking scientific mysteries and driving medical progress. Explore our product portfolio today and elevate your research to new heights.